Drug profile · INN
methocarbamol
METHOCARBAMOL
methocarbamol (METHOCARBAMOL) is a carbonic anhydrase i inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — methocarbamol
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
methocarbamol (METHOCARBAMOL) is a carbonic anhydrase i inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Carbonic anhydrase I inhibitor
Primary target: Carbonic anhydrase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is methocarbamol?
methocarbamol (METHOCARBAMOL) is a carbonic anhydrase i inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for methocarbamol?
METHOCARBAMOL is a marketed brand name for methocarbamol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methocarbamol?
methocarbamol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.